

9 October 2017 2017  
EMA/118465/2012 Rev 1\*

## Guideline on good pharmacovigilance practices (GVP) Module XV – Safety communication (Rev 1)

|  |                   |
|--|-------------------|
| Date for coming into effect of first version   | 24 January 2013   |
| Draft Revision 1* finalised by the Agency in collaboration with Member States                | 17 November 2015  |
| Draft Revision 1 agreed by the European Risk Management Facilitation Group (ERMS FG)         | 24 November 2015  |
| Draft Revision 1 adopted by Executive Director   | 8 December 2015   |
| Release for consultation   | 15 December 2015  |
| End of consultation (deadline for comments)  | 29 February 2016  |
| Revised draft Revision 1 finalised by the Agency in collaboration with Member States         | 27 September 2017 |
| Revised draft Revision 1 agreed by the EU Network Pharmacovigilance Oversight Group (EU-POG) | 4 October 2017    |
| Revised draft Revision 1 adopted by Executive Director as final                              | 9 October 2017    |
| Date for coming into effect of Revision 1*   | 13 October 2017   |

\*Note: Revision 1 contains the following:

- Introduction of the concept of core EU DHPC for situations where a common DHPC prepared at EU level may not be appropriate because of different requirements at the level of Member States (e.g. differences in available alternative treatments) and the PRAC/CHMP therefore agrees on core messages only (changes in XV.A., XV.B.2., XV.C.2.1. and XV.C.2.2.);
- Introduction of the option that one marketing authorisation holder may act on behalf of other marketing authorisation holders with a goal of disseminating one single DHPC in situations where several marketing authorisation holders are concerned (changes in XV.C.2.2.);
- Adjustments of references to other GVP Modules, given the recently revised GVP structure (see page 6 of GVP Introductory Note of 15 December 2015);
- Editorial improvements throughout the Module (changes in particular in XV.A., XV.B.2., XV.B.3, XV.B.5., XV.B.5.1., XV.B.5.2., XV.B.6., XV.C.1., XV.C.1.1., XV.C.1.2.);

See websites for contact details



- The revised GVP Annex II – DHPC template (EMA/36988/2013) and the new GVP Annex II – DHPC Communication Plan template (EMA/334164/2015) have been replicated at the end of the Module for ease of reference;

- After the public consultation, the outcome of work package 2 on communication and dissemination of the Strengthening Collaboration for Operating Pharmacovigilance in Europe (SCOPE) Joint Action of the Member States (see [www.scopejointaction.eu](http://www.scopejointaction.eu)) have become available and have been incorporated to the Module.

## Table of contents

|  |           |
|--|-----------|
| <b>XV.A. Introduction</b> .....  | <b>4</b>  |
| <b>XV.B. Structures and processes</b> .....  | <b>5</b>  |
| XV.B.1. Objectives of safety communication.....  | 5         |
| XV.B.2. Principles of safety communication.....  | 5         |
| XV.B.3. Target audiences.....  | 6         |
| XV.B.4. Content of safety communication.....   | 6         |
| XV.B.5. Means of safety communication.....   | 7         |
| XV.B.5.1. Direct healthcare professional communication (DHPC).....   | 7         |
| XV.B.5.2. Communication materials from competent authorities targeted at healthcare professionals.....             | 8         |
| XV.B.5.3. Documents in lay language to patients and the general public.....  | 8         |
| XV.B.5.4. Press communication.....   | 9         |
| XV.B.5.5. Website.....   | 9         |
| XV.B.5.6. Social media and other online communications.....  | 10        |
| XV.B.5.7. Bulletins and newsletters.....   | 10        |
| XV.B.5.8. Inter-authority communication.....   | 10        |
| XV.B.5.9. Responding to enquiries from the public.....   | 10        |
| XV.B.5.10. Other means of communication.....   | 10        |
| XV.B.6. Effectiveness of safety communication.....   | 10        |
| XV.B.7. Quality system requirements for safety communication.....  | 11        |
| <b>XV.C. Operation of the EU regulatory network</b> .....  | <b>11</b> |
| XV.C.1. Coordination of safety announcements in the EU.....  | 11        |
| XV.C.1.1. Process for exchange and coordination of safety announcements.....                                       | 12        |
| XV.C.1.2. Exchange of safety information produced by third parties.....  | 13        |
| XV.C.1.3. Requirements for the marketing authorisation holder in the EU.....                                       | 13        |
| XV.C.1.4. Consideration for third parties.....   | 13        |
| XV.C.1.5. Languages and translations.....  | 14        |
| XV.C.2. Direct healthcare professional communications (DHPCs) in the EU.....                                       | 14        |
| XV.C.2.1. Processing of DHPCs.....   | 14        |
| XV.C.2.2. Translation and dissemination of DHPCs.....  | 15        |
| XV.C.2.3. Publication of DHPCs.....  | 16        |
| Figure XV.1: Flow chart for the processing of Direct Healthcare Professional Communications (DHPCs) in the EU..... | 17        |
| <b>GVP Annex II – Templates: Direct Healthcare Professional Communication</b> .....                                | <b>18</b> |
| <b>GVP Annex II – Templates: Communication Plan for Direct Healthcare Professional Communication</b> .....         | <b>20</b> |

## XV.A. Introduction

This Module provides guidance to marketing authorisation holders, competent authorities in Member States and the European Medicines Agency on how to communicate and coordinate safety information concerning medicinal products authorised in the EU. Communicating safety information to patients and healthcare professionals is a public health responsibility and is essential for achieving the objectives of pharmacovigilance in terms of promoting the rational, safe and effective use of medicines, preventing harm from adverse reactions, minimising risks and contributing to the protection of patients' and public health (see [GVP Module I](#)).

Safety communication is a broad term covering different types of information on medicines, including statutory information as contained in the product information (i.e. the summary of product characteristics (SmPC), package leaflet (PL) and the labelling of the packaging) and public assessment reports. Although some principles in this Module (i.e. [XV.B.1.](#) and [XV.B.2.](#)) apply to all types of safety communication, the Module itself focuses on the communication of 'important new safety information', which means new information about a previously known or unknown risk of a medicine which has or could have an impact on a medicine's risk-benefit balance and its condition of use. Unless otherwise stated, the term 'safety communication' in this Module should be read as referring to new safety information.

Experience so far has demonstrated the need to coordinate safety communication within the EU regulatory network. High levels of public interest are anticipated when new safety concerns arise and it is important that clear and consistent messages are provided across the EU in a timely manner. The new legislation on pharmacovigilance therefore includes a number of provisions to strengthen safety communication and its coordination<sup>1</sup>.

Communication of important new safety information on medicinal products should take into account the views and expectations of concerned parties, including patients and healthcare professionals, with due consideration given to relevant legislation.

Communication, which in this Module refers to the active dissemination of safety information for an intended audience, is distinct from transparency. Transparency aims to provide public access to information related to data assessment, decision-making and safety monitoring performed by competent authorities. The new EU legislation on pharmacovigilance envisages an unprecedented level of transparency. Transparency provisions applicable to each pharmacovigilance process are provided in the relevant GVP Modules.

[XV.B.](#) of this Module describes principles and means of safety communication. [XV.C.](#) provides guidance on the coordination and dissemination of safety communication within the EU network. Both sections give particular consideration to direct healthcare professional communications (DHPCs), and provide specific guidance for preparing them. This is because of the level of coordination required between marketing authorisation holders and competent authorities in their preparation. The same principles also apply to proactive communications by competent authorities.

Throughout this Module, legal obligations are referred to as stated in the GVP Introductory Cover Note and are usually identified by the modal verb 'shall' (e.g. 'the marketing authorisation holder shall'). When guidance is provided on how to implement legal provisions, the modal verb 'should' is used (e.g. 'the marketing authorisation holder should').

---

<sup>1</sup> Directive 2010/84/EU amending Directive 2001/83/EC (the latter is referenced as DIR), Regulation (EU) No 1235/2010 amending Regulation (EC) No 726/2004 (the latter is referenced as REG) and in the Commission Implementing Regulation (EU) No 520/2012 on the performance of pharmacovigilance activities provided for in Regulation (EC) No 726/2004 and Directive 2001/83/EC (the Implementing Regulation is referenced as IR).

In Section B, the term “competent authority” is to be understood in its generic meaning of an authority regulating medicinal products and/or an authority appointed at national level for being in charge of all or individual pharmacovigilance processes. The term “competent authority” covers the relevant competent authorities in the EU Member States and the Agency.

## **XV.B. Structures and processes**

### ***XV.B.1. Objectives of safety communication***

Safety communication aims at:

- providing timely, evidence-based information on the safe and effective use of medicines;
- facilitating changes to healthcare practices (including self-medication practices) where necessary;
- changing attitudes, decisions and behaviours in relation to the use of medicines;
- supporting risk minimisation behaviour;
- facilitating informed decisions on the rational use of medicines.

In addition to the above effective, high-quality safety communication can support public confidence in the regulatory system.

### ***XV.B.2. Principles of safety communication***

The following principles of safety communication should be applied:

- Safety communication should deliver relevant, clear, accurate and consistent messages and reach the right audiences at the right time for them to take appropriate action.
- Safety communication should be tailored to the appropriate audiences (e.g. patients and healthcare professionals) by using appropriate language and taking account of the different levels of knowledge and information needs whilst maintaining the accuracy and consistency of the information conveyed.
- The need for communicating safety information should be considered throughout the pharmacovigilance and risk management process, and should be part of the risk assessment and risk minimisation measures.
- There should be adequate coordination and cooperation between the different parties involved in issuing safety communications (e.g. competent authorities, other public bodies and marketing authorisation holders).
- Information on risks should be presented in the context of the benefits of the medicine and include available and relevant information on the seriousness, severity, frequency, risk factors, time to onset, reversibility of potential adverse reactions and expected time to recovery.
- Safety communication should address the uncertainties related to a safety concern. This is of particular relevance for new information which is often communicated while competent authorities are conducting their evaluations; the usefulness of communication at this stage needs to be balanced against the potential for confusion if uncertainties are not properly represented.
- Information on competing risks such as the risk of non-treatment should be included where appropriate.

- The most appropriate quantitative measures should be used when describing and comparing risks, e.g. the use of absolute risks and not just relative risks; when comparing risks, denominators should be the same in size. The use of other tools such as graphical presentation of the risk and/or the risk-benefit balance may also be considered.
- Patients and healthcare professionals should, where possible, be consulted and messages pre-tested early in the preparation of safety communication, particularly on complex safety concerns.
- Where relevant safety communication should be complemented at a later stage with follow-up communication e.g. on the resolution of a safety concern or updated recommendations.
- The effectiveness of safety communication should be evaluated where appropriate and possible (see [XV.B.7.](#)).
- Safety communications should comply with relevant requirements relating to individual data protection and confidentiality.

### ***XV.B.3. Target audiences***

The primary target audiences for safety communication issued by competent authorities and marketing authorisation holders should be patients, carers and healthcare professionals who use (i.e. prescribe, handle, dispense, administer or take) medicinal products.

As primary target audiences, healthcare professionals play an essential role in ensuring that medicines are used as effectively and safely as possible. Effective safety communication enables them to take adequate actions to minimise risks and to give clear and useful information to their patients. This ultimately promotes patient safety and confidence in the regulatory system. Both healthcare professionals in clinical practice and those involved in clinical trials should be provided with appropriate information on any safety concern at the same time.

Patient, consumer and healthcare professional organisations can play a role as multipliers as they can disseminate important safety information to target audiences.

The media is also a target audience for safety communication. The capacity of the media to reach out to patients, healthcare professionals and the general public is a critical element for amplifying new and important information on medicines. The way safety information is communicated through the media will influence the public perception and it is therefore important that the media receives safety information directly from the competent authorities in addition to the information they receive from other sources.

### ***XV.B.4. Content of safety communication***

The information in the safety communication shall not be misleading and shall be presented objectively [DIR Art 106a(1)]. Safety information should not include any material or statement which might constitute advertising within the scope of Title VIII of Directive 2001/83/EC.

Therefore, taking into account the above provisions and the principles in [XV.B.2.](#), safety communication should contain:

- important new information on any authorised medicinal product which has an impact on the medicine's risk-benefit balance under any conditions of use;
- the reason for initiating safety communication clearly explained to the target audience;
- any recommendations to healthcare professionals and patients on how to deal with a safety concern;

- when applicable, a statement on the agreement between the marketing authorisation holder and the competent authority on the safety information provided;
- information on any proposed change to the product information (e.g. the summary of product characteristics (SmPC) or package leaflet (PL));
- any additional information about the use of the medicine or other data that may be relevant for tailoring the message to the targeted audience;
- a list of literature references, when relevant or a reference to where more detailed information can be found, and any other background information considered relevant;
- where relevant, a reminder of the need to report suspected adverse reactions in accordance with national spontaneous reporting systems.

### ***XV.B.5. Means of safety communication***

Communication tools and channels<sup>2</sup> have become more numerous and varied over time, offering the public more information than was previously possible. Relevant communication tools and channels should be considered when issuing a safety communication in order to reach the target audiences and meet their growing expectations. Different communication tools and channels are discussed below in [XV.B.5.1.](#) to [XV.B.5.9.](#)

#### **XV.B.5.1. Direct healthcare professional communication (DHPC)**

A direct healthcare professional communication (DHPC) is a communication intervention by which important safety information is delivered directly to individual healthcare professionals by a marketing authorisation holder or a competent authority, to inform them of the need to take certain actions or adapt their practices in relation to a medicinal product. DHPCs are not replies to enquiries from healthcare professionals.

The preparation of DHPCs involves cooperation between the marketing authorisation holder and the competent authority. Agreement between these two parties should be reached before a DHPC is issued by the marketing authorisation holder. The agreement will cover both the content of the DHPC (see [XV.B.4.](#)) and the communication plan (see GVP Annex II), including the intended recipients, the timetable and the channels for disseminating the DHPC.

Where there are several marketing authorisation holders of the same active substance and/or a class of products for which a DHPC is to be issued, a single consistent message should be delivered (see [XV.C.2.1.](#)).

Whenever possible and appropriate, it is advised that healthcare professionals' organisations or learned societies are involved during the preparation of DHPCs to ensure that the information delivered by the DHPCs is useful and adapted to the target audience.

A DHPC should be complemented by other communication tools and channels and the principle of providing consistent information should apply ([XV.B.2.](#)).

A DHPC should be included as an additional risk minimisation measure as part of a risk management plan (see [GVP Modules V and XVI](#)).

A DHPC should be disseminated in the following situations when there is a need to take immediate action or change current practice in relation to a medicinal product:

---

<sup>2</sup> For the purpose of this Section tools and channels are presented without distinction as they often overlap and there is no general agreement on their categorisation.

- suspension, withdrawal or revocation of a marketing authorisation for safety reasons;
- an important change to the use of a medicine due to the restriction of an indication, a new contraindication, or a change in the recommended dose due to safety reasons;
- a restriction in availability or discontinuation of a medicine with potential detrimental effects on patient care.

Other situations where dissemination of a DHPC should be considered are:

- new major warnings or precautions for use in the product information;
- new data identifying a previously unknown risk or a change in the frequency or severity of a known risk;
- new evidence that the medicinal product is not as effective as previously considered;
- new recommendations for preventing or treating adverse reactions or to avoid misuse or medication errors with the medicinal product;
- ongoing assessment of an important potential risk, for which data available at a particular point in time are insufficient to take regulatory action (in this case, the DHPC should encourage close monitoring of the safety concern in clinical practice and encourage reporting, and possibly provide information on how to minimise the potential risk).

A competent authority may disseminate or request the marketing authorisation holder to disseminate a DHPC in any situation where the competent authority considers it necessary for the continued safe and effective use of a medicinal product.

### **XV.B.5.2. Communication materials from competent authorities targeted at healthcare professionals**

Competent authorities can issue safety communications targeting healthcare professionals directly. These are usually published on the website of the competent authority. These communications often complement other means for communicating a safety concern (e.g. a DHPC) and are issued around the same time. They contain the competent authority's recommendations and advice for risk minimisation for healthcare professionals, and provide relevant background information. Adequate links to further information can be included (e.g. links to the product information of the concerned medicinal product(s) and, whenever possible, prescription and dispensing systems).

Safety communications from competent authorities should follow the principles identified above (see XV.B.2.) and should be issued when there is a need to take immediate action or change current practice in relation to a medicinal product (see XV.B.5.1.). Competent authorities should also consider existing public interest when issuing a safety communication.

Competent authorities should make use of the most appropriate tools and channels described in this Section to maximise dissemination and accessibility of relevant information. This includes interaction with other organisations such as learned societies, local health authorities, patient and other healthcare organisations, as appropriate.

### **XV.B.5.3. Documents in lay language to patients and the general public**

Communication material in lay language (e.g. using a questions & answers format) helps patients and the general public to understand the scientific evidence and regulatory actions relating to a safety concern. It can also be an additional tool that healthcare professionals can use in their communication with patients. Lay language documents should contain the competent authority's recommendations



and advice for risk minimisation for patients, and should be accompanied by relevant background information.

Lay language documents should be useful to members of the public who have an interest in the subject but do not have a scientific or regulatory background. Reference should be made to other communication materials on the topic to direct readers to where they can find further information.

For the dissemination and accessibility of lay language documents, the most appropriate tools and channels described in this Section should be used as appropriate.

Whenever possible and appropriate, it is advised that patients are involved during the preparation of lay language documents to ensure that the information they deliver is useful and adapted to the target audience.

#### **XV.B.5.4. Press communication**

Press communication includes press releases and press briefings which are primarily intended for journalists.

Competent authorities may send press releases directly to journalists in addition to publishing them on their websites. This ensures that journalists, in addition to obtaining information from other sources, receive information that is consistent with the authority's scientific assessment. Interaction with the media is an important way to reach out to a wider audience as well as to build trust in the regulatory system.

Press releases may also be prepared and published by marketing authorisation holders. Their press releases should make reference to the regulatory action taken by the competent authority. Relevant ongoing reviews should be mentioned in any communication by the marketing authorisation holder.

Although aimed at journalists, press releases will be read by other audiences such as healthcare professionals, patients and the general public. Reference should therefore be made to related communication materials on the topic. In cases where a DHPC and/or a communication from a competent authority is also prepared, healthcare professionals should ideally receive it prior to or around the same time of the publication or distribution of a press release so that they are better prepared to respond to patients.

Press briefings with journalists should be considered by competent authorities for safety concerns or other matters relating to the safety of medicinal products that are of high media interest or when complex or public-health-sensitive messages need to be conveyed.

#### **XV.B.5.5. Website**

A website is a key tool for members of the public (including patients and healthcare professionals) actively searching the internet for specific information on medicinal products. Competent authorities as well as marketing authorisation holders should ensure that important safety information published on websites under their control is easily accessible and understandable by the public. Information on websites should be kept up-to-date, with any information that is out-of-date marked as such or removed.

The applicable legislation on pharmacovigilance foresees the creation of an EU medicines web portal which will contain information on all medicines authorised in the EU [REG Art 26(1)]. This web portal will become a key tool for communicating up-to-date safety information to EU citizens and will contain information in all EU official languages. Each Member State shall set up and maintain a national medicines web-portal which shall be linked to the EU medicines web-portal [DIR Art 106]. Until the

web portal is fully established and into operation, the Agency's website will be acting as an interim platform to convey this important up-to-date safety information.

#### **XV.B.5.6. Social media and other online communications**

Online safety information may also be disseminated via social media and other web tools. When using newer, more rapid communication channels, special attention should be paid to ensure that the accuracy of the information released is not compromised. Communication practices should take into account emerging digital communication tools used by the various target audiences.

#### **XV.B.5.7. Bulletins and newsletters**

Bulletins and newsletters provide at regular intervals information about medicines and their safety and effectiveness. These tools may serve as reminders of previous communications. Competent authorities can reach a large audience with these tools by using web-based and other available means.

#### **XV.B.5.8. Inter-authority communication**

When one competent authority takes regulatory action on a particular safety concern, other competent authorities may also receive enquiries or may want to communicate on the same issue. The use of inter-authority communication material, such as lines-to-take should be considered. Lines-to-take are documents prepared by a competent authority to assist its staff and those of co-operating authorities in responding consistently to external enquires or communicating a consistent message on a specific issue.

#### **XV.B.5.9. Responding to enquiries from the public**

Competent authorities and marketing authorisation holders should have systems in place for responding to enquiries about medicines from individual members of the public. Responses should take into account the information which is in the public domain and should include the relevant recommendations to patients and healthcare professionals issued by competent authorities. Where questions relate to individual treatment advice, the patient should be advised to contact a healthcare professional.

In this respect, DIR Articles 86(2) and 98(1) apply to marketing authorisation holders.

#### **XV.B.5.10. Other means of communication**

In addition to those discussed above, there are other tools and channels such as publications in scientific journals and journals of professional bodies.

Some tools and channels may be used in the context of risk management; in addition to the product information, other communication tools can be used to disseminate information about the product. These are considered as additional risk minimisation measures and may include patient alert cards or educational materials. These are outside the scope of this Module and are described in more detail in [GVP Module XVI](#).

#### ***XV.B.6. Effectiveness of safety communication***

Safety communication is considered effective when the message transmitted is received and understood by the target audience in the way it was intended, and appropriate action is taken by the target audience. Where possible, mechanisms should be introduced in order to measure the

effectiveness of the communication. A research-based approach will normally be appropriate in order to establish that safety communications have met the standard of XV.B.2.. This approach may measure different outcomes, including behaviour, attitudes, and knowledge. When evaluating the effectiveness of safety communication, the scope of the evaluation may be broadened to include factors other than the performance of the individual tools used in the safety communication (see GVP Module XVI).

In the case of DHPCs, marketing authorisation holders should inform the relevant competent authorities about the number of healthcare professionals who received the DHPC and about any difficulty identified during the dissemination of the DHPCs (e.g. problems related to the list of recipients or the timing and mechanism of dissemination). Appropriate action should be taken as needed to correct the situation or prevent similar problems in the future.

### ***XV.B.7. Quality system requirements for safety communication***

In accordance with the quality system requirements in GVP Module I, procedures should be in place to ensure that safety communications comply with the principles in XV.B.2. as appropriate.

In particular, safety communications should be subject to quality controls to ensure their accuracy and clarity. For this purpose review procedures with allocated responsibilities should be followed and documented.

## **XV.C. Operation of the EU regulatory network**

### ***XV.C.1. Coordination of safety announcements in the EU***

In the EU, patients and healthcare professionals increasingly look at competent authorities as providers of important information on medicines. For safety communication to be effective, adequate coordination and cooperation is required within the EU regulatory network<sup>3</sup>. A good level of coordination of safety communication is of particular importance so that healthcare professionals and patients receive consistent information on regulatory decisions in the EU.

When issuing safety announcements, competent authorities may make use of the different tools and channels described in XV.B.5.. Prior to the publication of a safety announcement, the Member States, the Agency or the European Commission shall inform each other not less than 24 hours in advance, unless urgent public announcements are required for the protection of public health [DIR Art 106a(2)].

For active substances contained in medicinal products authorised in more than one Member State, the Agency shall be responsible for the coordination between national competent authorities of safety announcements and shall provide timetables for the information being made public [DIR Art 106a(3)].

For practical reasons, not all safety information made public by a Member State or the Agency will be subject to systematic coordination. Only safety announcements that relate to the following and that pertain to active substances contained in medicinal products authorised in more than one Member State require coordination within the EU regulatory network:

- the suspension, withdrawal or revocation of a marketing authorisation due to changes to its risk-benefit balance;
- the start or finalisation of an EU referral procedure for safety reasons;
- restriction of indication or treatment population or the addition of a new contraindication;

---

<sup>3</sup> i.e. the competent authorities in the Member States, the Agency and the European Commission.

- dissemination of a DHPC (see XV.C.2.1.);
- other emerging safety concerns judged by a national competent authority or the Agency to be likely to give rise to public or media interest in more than one Member State (e.g. a publication of important safety findings in a (scientific) journal, safety-related regulatory action taken in a Member State or in a country outside the EU).

### **XV.C.1.1. Process for exchange and coordination of safety announcements**

A competent authority of a Member State or the Agency shall inform the EU regulatory network prior to the publication of a safety announcement that pertains to active substances contained in medicinal products authorised in more than one Member State and that refer to any of the situations identified in XV.C.1.. It shall include a timetable for the information being made public [DIR Art 106a(3)].

Whenever possible the safety announcement shall be sent to the network under embargo not less than 24 hours prior to the publication [DIR Art 106a(2)], in order to allow the members of the EU regulatory network to prepare or plan their own communication, if necessary. Under the coordination of the Agency, the Member States shall make all reasonable efforts to agree on a common message in relation to the safety of the medicinal product concerned and the timetables for the distribution [DIR Art 106a(3)].

The Agency, together with the relevant Member States, should decide for each case, on the basis of the public health relevance and urgency of the safety concern, the population and number of Member States affected and the potential for media attention, whether further communication action in addition to the dissemination of the safety announcement is needed, such as:

- the preparation of lines-to-take (see XV.B.5.7.) for dissemination to the EU regulatory network. The lines-to-take document should help the EU regulatory network to respond to any request for information which may follow the publication of the safety announcement;
- the preparation of an Agency safety announcement in addition to that of the Member State, which should also be disseminated under embargo to the EU regulatory network together with a timetable for its publication.

The Agency should prepare lines-to-take documents and any Agency safety announcement together with the Member States who originated the process and the PRAC Lead Member State or the PRAC Rapporteur, as appropriate. The PRAC, as well as the CHMP or CMDh, should also be consulted as necessary.

Coordination of safety announcements should be done in cooperation with the concerned marketing authorisation holder(s). Whenever possible, the Agency and the competent authorities in the Member States should provide any safety announcement prior to its publication to the concerned marketing authorisation holder(s), together with the timetable for the information being made public. Any information of a personal or commercially confidential nature shall be deleted unless its public disclosure is necessary for the protection of public health [DIR Art 106a(4)].

The exchange and coordination of safety announcements within the EU regulatory network should make use of the EU Early Notification System (ENS). The ENS includes the Heads of Medicines Agencies (HMA), the members of the PRAC, CHMP, PDCO, CMDh, the operational contact points for safety announcements at the competent authority in the Member States, the European Commission and the Agency. Operational contact points should ensure that any information exchanged via the system reaches in a timely manner the relevant staff within each competent authority, including relevant staff working within the communications departments.

Safety announcements from the EU regulatory network should be shared with international partners, subject to embargo and any specific confidentiality arrangements in place.

As a complement to the coordination of safety announcements within the EU regulatory network, competent authorities in Member States and the Agency should interact with concerned stakeholders in the EU (mainly patients' and healthcare professionals' organisations), who can play a key role in reviewing and disseminating information to the end users (patients and healthcare professionals). It is recommended that national competent authorities and the Agency keep up-to-date contact details of relevant patients' and healthcare professionals' organisations.

### **XV.C.1.2. Exchange of safety information produced by third parties**

There are situations where new safety information is to be published or has been published by a party other than a competent authority of a Member State or the Agency (e.g. scientific journals, learned societies). Competent authorities should bring to the attention of the EU regulatory network any such safety information that they become aware of, together with the timing of the publication if known. Where necessary and after evaluation of the information, the Agency should prepare and disseminate a lines-to-take document or an Agency safety announcement to address the information from the third party (see XV.C.1.1.).

In the context of collaboration with authorities outside the EU, competent authorities may become aware of safety announcements to be published by authorities outside the EU. In these cases the Agency should, as necessary, prepare and disseminate lines-to-take or safety announcements within the EU regulatory network. In all cases, the terms of relevant confidentiality agreements with non-EU regulatory authorities and the embargoes on the information received should be respected.

### **XV.C.1.3. Requirements for the marketing authorisation holder in the EU**

As soon as a marketing authorisation holder in the EU intends to make a public announcement relating to information on pharmacovigilance concerns in relation to the use of a medicinal product, and in any event at the same time or before the public announcement is made, the marketing authorisation holder shall be required to inform the competent authorities in the Member States, the Agency and the European Commission [DIR Art 106a]. This should apply to announcements intended for the EU as well as outside the EU (when they concern medicinal products authorised in the EU or those for which an opinion under REG Article 58 has been given). Informing the competent authorities at the same time as the public (i.e. without advance notice to the competent authorities) should only occur exceptionally and under justified grounds. Whenever possible, the information should be provided under embargo at least 24 hours prior to its publication.

The marketing authorisation holder shall ensure that information to the public is presented objectively and is not misleading [DIR Art 106a].

Whenever a marketing authorisation holder becomes aware that a third party (see XV.C.1.2.) intends to issue communications that could potentially impact the risk-benefit balance of a medicinal product authorised in the EU, the marketing authorisation holder should inform the relevant competent authorities in Member States and the Agency and make every effort to share the content of the communications with the relevant competent authorities.

### **XV.C.1.4. Consideration for third parties**

Third parties (e.g. editors of scientific journals, learned societies, patients' organisations) are encouraged to inform the Agency and the competent authorities in the Member States of any relevant

new information on the safety of medicines authorised in the EU and, if publication is planned, to share the information ahead of publication.

### **XV.C.1.5. Languages and translations**

Consistent messages should reach the public across the EU in a timely manner and in the official languages of the Member States as specified by the Member States where the medicinal product is placed on the market.

For the purpose of coordination, the Agency shall use English to inform the EU regulatory network of any safety announcement. When informing the Agency, the competent authorities in the Member States are encouraged to provide English translations of their safety announcements for the purpose of initiating the coordination process within the network. In the absence of a full text translation, an English summary should be provided.

### **XV.C.2. Direct healthcare professional communications (DHPCs) in the EU**

In the EU, a direct healthcare professional communication (DHPC) (see XV.B.5.1.) is usually disseminated by one or a group of marketing authorisation holders for the respective medicinal product(s) or active substance(s), either at the request of a national competent authority or the Agency, or on the marketing authorisation holder's own initiative. The marketing authorisation holder should seek the agreement of the relevant national competent authorities or the Agency regarding the content of a DHPC (and communication plan) (see GVP Annex II) prior to dissemination.

#### **XV.C.2.1. Processing of DHPCs**

The situations when a DHPC is necessary or should be considered are provided in XV.B.5.1. When drafting a DHPC, the template (see GVP Annex II) and the guidance provided in the annotations in the template should be followed as appropriate.

The roles and responsibilities of the competent authorities in a Member State, the Agency and marketing authorisation holders in the preparation and processing of DHPCs depend on the route of authorisation of the medicinal products concerned:

- for centrally authorised medicinal products and for medicinal products subject to an EU procedure, the relevant marketing authorisation holders should submit the draft DHPC and communication plan (including the intended recipients and the timetable for disseminating the DHPC) (see GVP Annex II) to the Agency, which should coordinate the review process by its scientific committees (i.e. PRAC and CHMP) and CMDh.
- for medicinal products authorised through the mutual recognition or decentralised procedure, the marketing authorisation holder should submit the draft DHPC and communication plan to the Reference Member State, which should co-ordinate the process with the marketing authorisation holder, while keeping the concerned Member States involved in the process.
- for purely nationally authorised medicinal products, the marketing authorisation holder should submit the draft DHPC and any communication plan to the competent authorities of the Member States where the medicinal products are authorised.

The marketing authorisation holder should allow a minimum of two working days for comments during the review. However, whenever possible, more time should be allowed. The timing may be adapted according to the urgency of the situation.

The Agency will coordinate the review of DHPCs within its scientific committees/groups as appropriate (i.e. involvement of PRAC, and finalisation by CHMP or CMDh as relevant). The PRAC should always be involved in the review of DHPCs related to a safety concern being discussed at the PRAC and the DHPC should form part of the PRAC assessment. The Agency may also request advice from PRAC on issues related to other safety communications.

There might be situations where a single DHPC prepared at EU level may not be suitable as there may be differences in Member States (such as differences in available therapeutic alternatives) which cannot be addressed in a single DHPC. In such cases, it is proposed that a core EU DHPC is agreed at EU level setting out core EU messages. The core EU DHPC can then be complemented at national level with additional information to address the different national situations (i.e. in relation to availability and choice of alternative treatments).

Although there will be national tailoring of such DHPCs, any core messages agreed at EU level should be preserved (i.e. tailoring should not conflict with these core messages).

In each Member State, when several marketing authorisation holders are concerned (i.e. when the DHPC covers several products with the same active substance or products of the same therapeutic class), marketing authorisation holders are strongly encouraged to arrange for one marketing authorisation holder to act on behalf of all concerned marketing authorisation holders as the contact point for the national competent authority. Where generics are involved, the contact point should normally be the marketing authorisation holder of the originator product. If no originator product is marketed in a Member State, one of the concerned generic companies is encouraged to act as the contact point. Such coordination between concerned marketing authorisation holders aims to ensure that healthcare professionals in a given Member State receive a single DHPC covering all the medicinal products affected by a single safety concern (same active substance or a class review). The marketing authorisation holder acting as contact point for the national competent authority and on behalf of all other marketing authorisation holders should be specified in the agreed communication plan (see GVP Annex II) to facilitate coordination.

Once the content of a DHPC and communication plan from the marketing authorisation holder are agreed by national competent authorities or the Agency, the national competent authorities or the Agency should share the final DHPC and communication plan using the early notification system (see [XV.C.1.1.](#)), and the Agency or the national competent authority as relevant should coordinate any subsequent safety announcement as appropriate using the process described in [XV.C.1.1.](#). The early notification system is only used if the DHPC concerns an active substance authorised in more than one Member State.

In cases where an authority outside the EU requests the dissemination of a DHPC in their territory for a medicinal product also authorised in the EU, the marketing authorisation holder should notify the relevant competent authorities in the EU. This is part of the legal requirement under which the marketing authorisation holder shall notify the competent authorities of any new information which may impact the risk-benefit balance of a medicinal product [REG Art 16(2) and DIR 23(2)]. The need for any subsequent communication, e.g. a DHPC, in the EU should be considered and agreed on a case-by-case basis.

A flow chart describing the processing of DHPCs is provided in [Figure XV.1.](#)

### **XV.C.2.2. Translation and dissemination of DHPCs**

For centrally authorised medicinal products, medicinal products subject to an EU procedure and, in most cases, for medicinal products authorised through the mutual recognition or decentralised procedure, the working language for preparing the DHPCs will normally be English.


Once the text of the DHPC is agreed, the marketing authorisation holder should prepare translations in the official languages of the Member States, as specified by the Member States where the DHPC is to be distributed. The draft translations should be submitted to the Member States for a language review and such review should be done within a reasonable timeframe which should not exceed 4-5 working days. Member States should aim at reviewing the translations ideally within 48 hours.

For centrally authorised medicinal products and medicinal products subject to an EU procedure, the relevant marketing authorisation holder should provide the Agency with a complete set of all final EU official language versions as well as any additional related communication documents.

### **XV.C.2.3. Publication of DHPCs**

The competent authorities may publish the final DHPC. The marketing authorisation holder will be informed of the intent to publish the DHPC so that the timing for such publication is aligned to that of the dissemination of DHPC in the Member States. The competent authorities in the Member States may also issue an additional safety announcement (see XV.B.5.2.), and disseminate them to relevant healthcare professionals' organisations as appropriate.





<sup>1</sup> The Agency will coordinate the review of DHPC within its scientific committees (i.e. PRAC and CHMP) and CMDh.

MAH: Marketing Authorisation Holder  
 NCAs: National Competent Authorities  
 MR: Mutual Recognition  
 DP: Decentralised Procedure  
 TT: Timetable

**Figure XV.1: Flow chart for the processing of Direct Healthcare Professional Communications (DHPCs) in the EU**

## GVP Annex II – Templates: Direct Healthcare Professional Communication<sup>4</sup>

*Note: This is an identical replication of GVP Annex II – Templates: DHPC Rev 1 (EMA/36988/2013 Rev 1) in this Module for ease of reference.*

<Date>

**<Active substance, name of medicinal product and main message  
(e.g. introduction of a warning or a contraindication)>**

Dear Healthcare professional,

<Name of marketing authorisation holder> in agreement with <the European Medicines Agency> and the <National Competent Authority > would like to inform you of the following:

### **Summary**

*Guidance: This section should be in bold/larger font size than the other sections of the DHPC and preferably in bullet points.*

- <Brief description of the safety concern in the context of the therapeutic indication, recommendations for risk minimisation (e.g. *contraindications, warnings, precautions of use*) and, if applicable, switch to alternative treatment>
- <Recall information, if applicable, including level (pharmacy or patient) and date of recall>

### **Background on the safety concern**

*Guidance: This section may include the following information:*

<Brief description of the therapeutic indication of the medicinal product>

<Important details about the safety concern (adverse reaction, seriousness, statement on the suspected causal relationship, and, if known, the pharmacodynamic mechanism, temporal relationship, positive re-challenge or de-challenge, risk factors)>

<An estimation of the frequency of the adverse reaction or reporting rates with estimated patient exposure>

<A statement indicating any association between the adverse reaction and off-label use, if applicable>

<If applicable, details on the recommendations for risk minimisation>

<A statement if the product information is to be or has been revised, including a description of the changes made or proposed> *Guidance: No need however to include or attach the precise (translated) text of the product information which, at the time of dissemination of the DHPC may not be available as final approved translations)*

<Place of the risk in the context of the benefit>

<The reason for disseminating the DHPC at this point in time>

<Any evidence supporting the recommendation (e.g. include citation(s) of key study/ies)>

<A statement on any previous DHPCs related to the current safety concern that have recently been disseminated>

---

<sup>4</sup> This template should also be used for the preparation of a core EU DHPC (see XV.C.2.1.).

<Any schedule for follow-up action(s) by the marketing authorisation holder/competent authority, if applicable>

### ***Call for reporting***

<A reminder of the need and how to report adverse reactions in accordance with the national spontaneous reporting system, including the details (e.g. name, postal address, fax number, website address) on how to access the national spontaneous reporting system>

<For biological medicinal products, also include a reminder to report the product name and batch details>.

<Mention if product is subject to additional monitoring and the reason why>

### ***Company contact point***

<Contact point details for access to further information, including relevant website address(es), telephone numbers and a postal address>

### ***Annexes (if applicable)***

<Link/reference to other available relevant information, such as information on the website of a competent authority>

<Additional scientific information, if applicable>

<List of literature references, if applicable>

## GVP Annex II – Templates: Communication Plan for Direct Healthcare Professional Communication

*Note: This is an identical replication of GVP Annex II – Templates: Communication Plan for DHPC (EMA/334164/2015) in this Module for ease of reference.*

| DHPC COMMUNICATION PLAN  |   |
|--|---|
| <b>Medicinal product(s)/active substance(s)</b>  |   |
| <b>Marketing authorisation holder(s)</b>   | <p><i>In cases where the DHPC concerns several marketing authorisation holders of the same active substance or is part of a class review, it is strongly encouraged that a single consistent message is sent to healthcare professionals in each EU Member State.</i></p> <p><i>All concerned marketing authorisation holders in each Member State are strongly encouraged to collaborate, so that a single DHPC is prepared and circulated in each Member State. The letter circulated in each Member State should cover all active substance-containing products authorised in that Member State.</i></p> <p><i>It is encouraged that the originator marketing authorisation holder (where available) in each Member State acts as the contact point for the national competent authority, on behalf of the other concerned marketing authorisation holders in the same Member State. If no originator product is marketed in the Member State, it is encouraged that one of the concerned generic companies acts as contact point for the competent authority.</i></p> |
| <b>Safety concern and purpose of the communication</b>                                 | <p><i>Consider using the title of the DHPC to describe the safety concern</i></p>   |
| <b>DHPC recipients</b>   | <p><i>List all (groups of) recipients of the DHPC in this section, e.g. general practitioners, specialists, community pharmacists, hospital pharmacists, nurses, professional societies, national associations.</i></p>   |
| <b>Member States where the DHPC will be distributed</b>                                |   |
| Timetable <i>Delete steps which are not applicable</i>                                 |   |
| <b>DHPC and communication plan (in English) agreed by PRAC</b>                         | <b>Date</b>   |
| <b>DHPC and communication plan (in English) agreed by CHMP/CMDh</b>                    |   |
| <b>Submission of translated DHPCs to the national competent authorities for review</b> |   |
| <b>Agreement of translations by national competent authorities</b>                     |   |
| <b>Dissemination of DHPC</b>   |   |